DataMeds AI said Corexa Pharmacy recorded preliminary, unaudited revenue above $1 million in September 2026, more than 66% higher than July 2026 revenue. The company attributed the update to retail-customer growth and launches of Tollo Health supplements and medical foods; the figures remain preliminary and unaudited.
Stories, market investigations, social-media posts, videos and graphics are for educational and informational purposes only. They are not investment, financial or trading advice, or a recommendation to buy, sell or hold any asset. Terms of Service
The September revenue claim is verified only as a company-issued preliminary, unaudited statement—not as an audited or SEC-reported result. As of the October 1, 2026 retrieval date, the latest located Form 10-Q covered the six months ended June 30, 2026, so it cannot confirm September revenue. The next required test is the filing covering the quarter ended September 30, 2026, or an audited disclosure that separately identifies Corexa Pharmacy revenue.
The claim is directionally positive at the operating-update level, but its consolidated financial significance is unclear. The SEC-recorded company-wide revenue for the quarter ended June 30, 2026 was $1.780 million, while consolidated gross profit was only $182,204, implying an approximate 10.2% gross margin. Consolidated operating loss was $7.345 million for that quarter. A single division's preliminary monthly revenue above $1 million therefore cannot establish consolidated profitability or margin improvement without segment-level revenue recognition, cost-of-revenue, and consolidation data.
The primary announcement states that Corexa Pharmacy, a division of wholly owned Corexa Health, recorded preliminary, unaudited September 2026 revenue above $1 million and more than 66% above July 2026 revenue. It also attributes growth to retail-customer expansion and Tollo Health product launches. These are company assertions, and the release expressly warns that the September result is preliminary and subject to change.
The latest SEC 10-Q available in the retrieved filing set was filed August 17, 2026 for the period ended June 30, 2026. It identifies one operating and reportable segment and reports consolidated—not September or Corexa-specific—results. SEC XBRL facts show June-quarter revenue of $1,779,860 and gross profit of $182,204. The same filing reports a six-month 2026 net loss of $26.106 million and operating cash use of $6.307 million. These figures provide important context against the thesis: the available audited/SEC evidence does not yet show that the reported monthly growth translated into improved consolidated economics.
Historical MEDS bars show a sharp price and volume move during September 2026, including a close rising from $0.8653 on September 14 to $1.62 on September 15, then $6.07 on September 16, with volume of approximately 65.1 million and 188.8 million shares respectively. The announcement was published October 1, after that move. This timing means the retrieved data do not support attributing the September price move to the October 1 Corexa announcement. Other corporate events, including September 2026 filings and reported liability/share transactions, remain possible explanations, but causation is unresolved.
Confirmation would require the next Form 10-Q, 10-K, or other eligible SEC financial disclosure that separately reports Corexa Pharmacy September revenue above $1 million, or reconciles the division's revenue to consolidated revenue under the applicable accounting basis. To establish financial improvement, the same disclosure must show comparable consolidated revenue, gross profit, and gross margin for the September quarter and explain the contribution of Corexa and Tollo Health products. Evidence against the thesis would be a filing showing September Corexa revenue below $1 million, a material post-announcement adjustment, no corresponding consolidated revenue increase, or unchanged/deteriorating gross margin.
A causal market conclusion would require an event-time study around the October 1 announcement using completed regular-session MEDS bars, market and sector controls, and ideally liquidity/flow data. The current evidence shows temporal inconsistency with the largest September price move and does not establish causation.
The evidence supports a conditional positive operating signal, not confirmation of audited revenue or consolidated margin improvement. The appropriate decision is to wait for the September 30, 2026 quarter filing and its segment/revenue-recognition detail; until then, the narrow thesis remains insufficiently confirmed.
The company announcement dated October 1, 2026 says Corexa Pharmacy recorded preliminary, unaudited revenue of more than $1 million for September 2026.
DataMeds AI via ACCESS NewswireThe same release states September revenue increased more than 66% from revenue reported for July 2026.
DataMeds AI via ACCESS NewswireSEC XBRL facts report consolidated revenue of $1,779,860 for April 1 through June 30, 2026. This is company-wide quarterly revenue, not Corexa-specific September revenue.
U.S. Securities and Exchange Commission Company FactsDaily bars show closes of $1.62 on September 15 and $6.07 on September 16, with approximately 65.1 million and 188.8 million shares traded, respectively.
Historical MEDS daily barsThe latest located 10-Q was filed August 17, 2026 and covers the period ended June 30, 2026; therefore it predates September and cannot audit or report September revenue.
U.S. Securities and Exchange CommissionQ2 2026 consolidated gross profit was $182,204 on $1,779,860 revenue, approximately 10.2% gross margin. The same quarter had a $7,345,054 operating loss, so the preliminary division datapoint does not establish improved consolidated profitability.
U.S. Securities and Exchange Commission Company FactsThe largest retrieved price and volume spike occurred September 15-16, before the announcement was published on October 1. This does not identify the true cause, but it weighs against attributing that move to this announcement.
Historical MEDS daily bars and ACCESS Newswire announcementThe announcement labels September revenue preliminary and unaudited and describes future growth expectations as management statements rather than reported results.
DataMeds AI via ACCESS NewswireThe exact next Form 10-Q, Form 10-K, or other eligible SEC disclosure covering September 30, 2026 is required to determine whether revenue exceeded $1 million after audit and accounting adjustments.
Corexa is described as a division of wholly owned Corexa Health, while the SEC filing reports one consolidated operating segment. A segment-to-consolidated reconciliation is needed to quantify materiality.
No retrieved filing reports the quarter ended September 30, 2026. Without consolidated revenue and cost of revenue for that quarter, margin improvement cannot be measured.
The release provides only a percentage comparison to July, not the exact July revenue, recognition policy, returns/allowances, or whether the amounts are gross or net revenue.
The retrieved bars show major MEDS activity before October 1, but no event-study controls, order-flow data, institutional positioning, or contemporaneous catalyst decomposition were retrieved.
Question tested: Does Corexa Pharmacy's September 2026 revenue exceed $1 million in the next audited or SEC-reported financial disclosure, and does the reported growth translate into consolidated revenue and gross-margin improvement?
The event is verified as a company-issued preliminary announcement, but not as audited or SEC-reported September revenue. Available SEC data show Q2 2026 consolidated revenue of $1.780 million, gross profit of $182,204, and operating loss of $7.345 million, which do not establish margin improvement. The largest retrieved MEDS price move occurred before the October 1 announcement, so causation is unproven. The assessment would change with the September 30, 2026 filing showing Corexa revenue above $1 million, its consolidated contribution, and improved gross margin.
Open the full Augur reportStories reflect the evidence available at their stated cutoff, not a live market view. Prices, facts and conclusions may change. Check the dates, underlying sources and full assessment before relying on a summary.